scholarly journals Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome

2004 ◽  
Vol 25 (4) ◽  
pp. 349-355 ◽  
Author(s):  
M Trøseid
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Levels ◽  
The Metabolic Syndrome

P6191Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
C Caselli ◽  
R Ragusa ◽  
S Del Turco ◽  
G Basta ◽  
A Saraste ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Metabolic Syndrome ◽  
Coronary Artery ◽  
Plasma Levels ◽  
Hdl Cholesterol ◽  
Homa Index ◽  
Cholesterol Levels ◽  
The Metabolic Syndrome ◽  
Artery Disease ◽  
Stable Cad

Abstract Background PCSK9 is a key regulator of serum LDL-cholesterol levels. The relation of PCSK9 with other components of cardiovascular and coronary artery disease (CAD) risk is still debated. Purpose To evaluate the association of PCSK9 plasma levels with cardiovascular and coronary risk profile, in patients with symptoms of suspected stable CAD enrolled in the EVINCI study. Methods PCSK9 was measured in 522 patients (60.4±8.8 years, 318 males) with symptoms of stable CAD Individual risk was characterized by clinical and bio-humoral variables, including lipid/glucose/inflammatory profiles. Obstructive CAD was firstly ruled-in by multimodality non-invasive imaging and, subsequently, assessed by invasive coronary angiography. Results Patients were divided into groups according to PCSK9 quartiles: I (<138 ng/mL), II-III (138–264 ng/mL), and IV (>264 ng/mL) (Table). The prevalence of obstructive CAD at invasive angiography and statin treatment did not differ among groups. Compared with patients in quartile IV, patients in quartile I, had a higher prevalence of metabolic syndrome and higher values of body mass index. Among biomarkers, all cholesterol lipoproteins levels progressively increased from quartile I to IV, while insulin and HOMA index values decreased (Table). At multivariable analyses adjusted for medical treatment, the only clinical or bio-humoral variables independently associated with PCSK9 levels were presence of the metabolic syndrome (Coeff. −0.195, SE 0.05, p<0.0001) and HDL cholesterol levels (Coeff. 0.444, SE 0.06, p<0.0001), respectively. Table 1 Clinical Variables Quartile I Quartile II–III Quartile IV Biomarkers Quartile I Quartile II–III Quartile IV <138 ng/L 138–264 ng/L >264 ng/L <138 ng/L 138–264 ng/L >264 ng/L (n=130) (n=261) (n=131) (n=130) (n=261) (n=131) Age, years 61±9 60±9 61±8 Glucose, mg/dL 110±30 117±41 109±29 Male gender 86 (66) 161 (62) 71 (55) Insulin, mUI/mL 13.3±12.5* 11.3±10.1 10.3±10.1 Family history 38 (29)# 86 (33) 58 (44) HOMA index 3.9±4.5* 3.5±4.1 2.9±3.3 Hypertension 78 (60) 164 (63) 88 (67) Tryglicerides, mg/dL 128±86 128±87 118±68 Hypercholesterolemia 72 (55) 158 (61) 81 (62) Total cholesterol, mg/dL 171±43* 181±45 203±55 Diabetes mellitus 43 (33) 91 (35) 37 (28) LDL, mg/dL 99±36* 104±38 119±45 Metabolic Syndrome 45 (35)# 72 (28) 19 (15) HDL, mg/dL 46±13* 52±15 61±19 BMI, kg/m2 28.02±4.00* 28.03±4.25 26.95±4.56 Total/HDL cholesterol 3.8±1.2* 3.7±1.2 3.5±1.1 Significant CAD at ICA 18 (14) 46 (18) 24 (18) hs-CRP, mg/dL 0.41±0.61 0.39±1.38 0.41±0.83 Statins treatment 68 (52) 143 (55) 58 (44) Interleukin 6, ng/L 1.60±2.75 1.30±2.49 1.30±1.68 Chi square test: #p<0.05. ANOVA: I vs. IV Quartile: *p<0.05. Conclusion In patients with stable CAD, low plasma levels of PCSK9 are associated with the prevalence of metabolic syndrome and its individual components, including, in particular, HDL cholesterol. Acknowledgement/Funding AMGEN grant, EU FP7-CP-FP506 2007 project (grant agreement no. 222915)

Imidazoline-like drugs improve insulin sensitivity through peripheral stimulation of adiponectin and AMPK pathways in a rat model of glucose intolerance

2015 ◽  
Vol 309 (2) ◽  
pp. E95-E104 ◽  
Author(s):  
Maud Weiss ◽  
Soumaya Bouchoucha ◽  
Farouk Aiad ◽  
Estelle Ayme-Dietrich ◽  
Nassim Dali-Youcef ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Glucose Intolerance ◽  
Rat Model ◽  
Plasma Levels ◽  
Improve Insulin Sensitivity ◽  
The Metabolic Syndrome ◽  
Ampk Phosphorylation ◽  
Stimulation Of

Altered adiponectin signaling and chronic sympathetic hyperactivity have both been proposed as key factors in the pathogenesis of metabolic syndrome. We recently reported that activation of I1 imidazoline receptors (I1R) improves several symptoms of the metabolic syndrome through sympathoinhibition and increases adiponectin plasma levels in a rat model of metabolic syndrome (Fellmann L, Regnault V, Greney H, et al. J Pharmacol Exp Ther 346: 370–380, 2013). The present study was designed to explore the peripheral component of the beneficial actions of I1R ligands (i.e., sympathoinhibitory independent effects). Aged rats displaying insulin resistance and glucose intolerance were treated with LNP509, a peripherally acting I1R agonist. Glucose tolerance, insulin sensitivity, and adiponectin signaling were assessed at the end of the treatment. Direct actions of the ligand on hepatocyte and adipocyte signaling were also studied. LNP509 reduced the area under the curve of the intravenous glucose tolerance test and enhanced insulin hypoglycemic action and intracellular signaling (Akt phosphorylation), indicating improved glucose tolerance and insulin sensitivity. LNP509 stimulated adiponectin secretion acting at I1R on adipocytes, resulting in increased plasma levels of adiponectin; it also enhanced AMPK phosphorylation in hepatic tissues. Additionally, I1R activation on hepatocytes directly enhanced AMPK phosphorylation. To conclude, I1R ligands can improve insulin sensitivity acting peripherally, independently of sympathoinhibition; stimulation of adiponectin and AMPK pathways at insulin target tissues may account for this effect. This may open a promising new way for the treatment of the metabolic syndrome.

scholarly journals Genetic Architecture of the APM1 Gene and Its Influence on Adiponectin Plasma Levels and Parameters of the Metabolic Syndrome in 1,727 Healthy Caucasians

Diabetes ◽  
2006 ◽  
Vol 55 (2) ◽  
pp. 375-384 ◽  
Author(s):  
I. M. Heid ◽  
S. A. Wagner ◽  
H. Gohlke ◽  
B. Iglseder ◽  
J. C. Mueller ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Levels ◽  
Genetic Architecture ◽  
The Metabolic Syndrome

OP025 ASSOCIATION OF GHRELIN LEU72MET POLYMORPHISM WITH SATIETY, GHRELIN PLASMA LEVELS AND TRAITS OF THE METABOLIC SYNDROME

2010 ◽  
Vol 5 (2) ◽  
pp. 11
Author(s):  
P. Rubin ◽  
I. Bastian ◽  
M.J. Miiller ◽  
J. Schrezenmeir ◽  
F. Döring
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Levels ◽  
The Metabolic Syndrome

The association of complement C3 genotype with coronary artery disease, markers of the metabolic syndrome and C3 plasma levels

2006 ◽  
Vol 95 (02) ◽  
pp. 393-395 ◽  
Author(s):  
Ramzi A. Ajjan ◽  
Timothy S. Futers ◽  
Jane M. Brown ◽  
Angela M. Carter ◽  
Peter J. Grant
Keyword(s):  
Coronary Artery Disease ◽  
Metabolic Syndrome ◽  
Coronary Artery ◽  
Plasma Levels ◽  
Complement C3 ◽  
The Metabolic Syndrome ◽  
Disease Markers ◽  
Artery Disease

scholarly journals Plasma levels of inflammatory cytokines in adult Nigerians with the metabolic syndrome

2016 ◽  
Vol 57 (1) ◽  
pp. 64 ◽  
Author(s):  
UdenzeIfeoma Christiana ◽  
AmadiE Casimir ◽  
AwololaAwodele Nicholas ◽  
MakweC Christian ◽  
AjieI Obiefuna
Keyword(s):  
Metabolic Syndrome ◽  
Inflammatory Cytokines ◽  
Plasma Levels ◽  
The Metabolic Syndrome

scholarly journals Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Chiara Caselli ◽  
Serena Del Turco ◽  
Rosetta Ragusa ◽  
Valentina Lorenzoni ◽  
Michiel De Graaf ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Levels ◽  
Coronary Atherosclerosis ◽  
Multivariable Analysis ◽  
Hdl Cholesterol ◽  
Metabolic Phenotype ◽  
Atherosclerotic Burden ◽  
The Metabolic Syndrome ◽  
Low Hdl ◽  
Inflammatory Profile

Abstract Objective Aim of this study was to evaluate the relationship of plasma PCSK9 with metabolic and inflammatory profile and coronary atherosclerotic burden in patients with suspected CAD enrolled in the EVINCI study. Methods PCSK9 was measured in 539 patients (60.3 ± 8.6 years, 256 males) with symptoms of CAD characterized by risk factors, bio-humoral profiles, and treatment. N = 412 patients underwent coronary computed tomography angiography (CTA) to assess the presence and characteristics of coronary atherosclerosis. A CTA score, combining extent, severity, composition, and location of plaques was computed. Results Patients were divided according to PCSK9 quartiles: I (< 136 ng/mL), II–III (136–266 ng/mL), and IV quartile (> 266 ng/mL). Compared with patients in quartile IV, patients in quartile I had a higher prevalence of the metabolic syndrome and higher values of body mass index. LDL- and HDL-cholesterol were significantly lower in patients in the quartile I than in those in quartile IV. Coronary CTA documented normal vessels in 30% and obstructive CAD in 35% of cases without differences among PCSK9 quartiles. Compared with patients with the highest levels, patients with the lowest PCSK9 levels had a higher CTA score mainly due to higher number of mixed non-obstructive coronary plaques. At multivariable analysis including clinical, medications, and lipid variables, PCSK9 was an independent predictor of the CTA score (coefficient − 0.129, SE 0.03, P < 0.0001), together with age, male gender, statins, interleukin-6, and leptin. Conclusion In patients with stable CAD, low PCSK9 plasma levels are associated with a particular metabolic phenotype (low HDL cholesterol, the metabolic syndrome, obesity, insulin resistance and diabetes) and diffuse non-obstructive coronary atherosclerosis. Trial registration ClinicalTrials.gov NCT00979199. Registered September 17, 2009

scholarly journals Associations of plasma very-long-chain SFA and the metabolic syndrome in adults

2018 ◽  
Vol 120 (8) ◽  
pp. 855-862
Author(s):  
Jing Zhao ◽  
Xiaofan Li ◽  
Xiang Li ◽  
Qianqian Chu ◽  
Yunhua Zhou ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Levels ◽  
Biological Activities ◽  
Population Characteristics ◽  
Chinese Adults ◽  
The Metabolic Syndrome ◽  
Metabolically Healthy ◽  
Underlying Mechanisms ◽  
Long Chain

AbstractPlasma levels of very-long-chain SFA (VLCSFA) are associated with the metabolic syndrome (MetS). However, the associations may vary by different biological activities of individual VLCSFA or population characteristics. We aimed to examine the associations of VLCSFA and MetS risk in Chinese adults. Totally, 2008 Chinese population aged 35–59 years were recruited and followed up from 2010 to 2012. Baseline MetS status and plasma fatty acids data were available for 1729 individuals without serious diseases. Among 899 initially metabolically healthy individuals, we identified 212 incident MetS during the follow-up. Logistic regression analysis was used to estimate OR and 95 % CI. Cross-sectionally, each VLCSFA was inversely associated with MetS risk; comparing with the lowest quartile, the multivariate-adjusted OR for the highest quartile were 0·18 (95 % CI 0·13, 0·25) for C20 : 0, 0·26 (95 % CI 0·18, 0·35) for C22 : 0, 0·19 (95 % CI 0·13, 0·26) for C24 : 0 and 0·16 (0·11, 0·22) for total VLCSFA (all Pfor trend<0·001). The associations remained significant after further adjusting for C16 : 0, C18 : 0, C18 : 3n-3, C22 : 6n-3, n-6 PUFA and MUFA, respectively. Based on follow-up data, C20 : 0 or C22 : 0 was also inversely associated with incident MetS risk. Among the five individual MetS components, higher levels of VLCSFA were most strongly inversely associated with elevated TAG (≥1·7 mmol/l). Plasma levels of VLCSFA were significantly and inversely associated with MetS risk and individual MetS components, especially TAG. Further studies are warranted to confirm the findings and explore underlying mechanisms.

Sign in / Sign up

Export Citation Format

Share Document